Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice

Francesco Massari, Vincenzo Di Nunno, Veronica Mollica, Rodolfo Montironi, Liang Cheng, Alessia Cimadamore, Ana Blanca, Antonio Lopez-Beltran

Research output: Contribution to journalReview article

Abstract

Management of metastatic renal cell carcinoma has been enriched by the advent of new therapeutic compounds. The approval of new combination strategies between targeted agents and immune-checkpoint inhibitors as well as the administration of combinations between immune-checkpoint inhibitors has clearly demonstrated significant improvement toward patients' prognosis and other clinical outcomes. Due to the availability of different treatments, the choice between them may be a difficult issue in our clinical practice. We have summarized current knowledge about available treatments focusing on criteria, which may help clinicians to make decisions.

Original languageEnglish (US)
Pages (from-to)1507-1521
Number of pages15
JournalImmunotherapy
Volume11
Issue number17
DOIs
StatePublished - Jan 1 2019

Fingerprint

Poverty
Renal Cell Carcinoma
Immunotherapy
Therapeutics

Keywords

  • atezolizumab
  • avelumab
  • combination strategies
  • immune-checkpoint inhibitors
  • immunotherapy
  • ipilimumab
  • metastatic renal cell
  • nivolumab
  • pembrolizumab
  • renal cell carcinoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Massari, F., Nunno, V. D., Mollica, V., Montironi, R., Cheng, L., Cimadamore, A., ... Lopez-Beltran, A. (2019). Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. Immunotherapy, 11(17), 1507-1521. https://doi.org/10.2217/imt-2019-0115

Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. / Massari, Francesco; Nunno, Vincenzo Di; Mollica, Veronica; Montironi, Rodolfo; Cheng, Liang; Cimadamore, Alessia; Blanca, Ana; Lopez-Beltran, Antonio.

In: Immunotherapy, Vol. 11, No. 17, 01.01.2019, p. 1507-1521.

Research output: Contribution to journalReview article

Massari, F, Nunno, VD, Mollica, V, Montironi, R, Cheng, L, Cimadamore, A, Blanca, A & Lopez-Beltran, A 2019, 'Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice', Immunotherapy, vol. 11, no. 17, pp. 1507-1521. https://doi.org/10.2217/imt-2019-0115
Massari F, Nunno VD, Mollica V, Montironi R, Cheng L, Cimadamore A et al. Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. Immunotherapy. 2019 Jan 1;11(17):1507-1521. https://doi.org/10.2217/imt-2019-0115
Massari, Francesco ; Nunno, Vincenzo Di ; Mollica, Veronica ; Montironi, Rodolfo ; Cheng, Liang ; Cimadamore, Alessia ; Blanca, Ana ; Lopez-Beltran, Antonio. / Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. In: Immunotherapy. 2019 ; Vol. 11, No. 17. pp. 1507-1521.
@article{4b6d4ef1381547eeb2a3b62d6bfbad17,
title = "Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice",
abstract = "Management of metastatic renal cell carcinoma has been enriched by the advent of new therapeutic compounds. The approval of new combination strategies between targeted agents and immune-checkpoint inhibitors as well as the administration of combinations between immune-checkpoint inhibitors has clearly demonstrated significant improvement toward patients' prognosis and other clinical outcomes. Due to the availability of different treatments, the choice between them may be a difficult issue in our clinical practice. We have summarized current knowledge about available treatments focusing on criteria, which may help clinicians to make decisions.",
keywords = "atezolizumab, avelumab, combination strategies, immune-checkpoint inhibitors, immunotherapy, ipilimumab, metastatic renal cell, nivolumab, pembrolizumab, renal cell carcinoma",
author = "Francesco Massari and Nunno, {Vincenzo Di} and Veronica Mollica and Rodolfo Montironi and Liang Cheng and Alessia Cimadamore and Ana Blanca and Antonio Lopez-Beltran",
year = "2019",
month = "1",
day = "1",
doi = "10.2217/imt-2019-0115",
language = "English (US)",
volume = "11",
pages = "1507--1521",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "17",

}

TY - JOUR

T1 - Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice

AU - Massari, Francesco

AU - Nunno, Vincenzo Di

AU - Mollica, Veronica

AU - Montironi, Rodolfo

AU - Cheng, Liang

AU - Cimadamore, Alessia

AU - Blanca, Ana

AU - Lopez-Beltran, Antonio

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Management of metastatic renal cell carcinoma has been enriched by the advent of new therapeutic compounds. The approval of new combination strategies between targeted agents and immune-checkpoint inhibitors as well as the administration of combinations between immune-checkpoint inhibitors has clearly demonstrated significant improvement toward patients' prognosis and other clinical outcomes. Due to the availability of different treatments, the choice between them may be a difficult issue in our clinical practice. We have summarized current knowledge about available treatments focusing on criteria, which may help clinicians to make decisions.

AB - Management of metastatic renal cell carcinoma has been enriched by the advent of new therapeutic compounds. The approval of new combination strategies between targeted agents and immune-checkpoint inhibitors as well as the administration of combinations between immune-checkpoint inhibitors has clearly demonstrated significant improvement toward patients' prognosis and other clinical outcomes. Due to the availability of different treatments, the choice between them may be a difficult issue in our clinical practice. We have summarized current knowledge about available treatments focusing on criteria, which may help clinicians to make decisions.

KW - atezolizumab

KW - avelumab

KW - combination strategies

KW - immune-checkpoint inhibitors

KW - immunotherapy

KW - ipilimumab

KW - metastatic renal cell

KW - nivolumab

KW - pembrolizumab

KW - renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85076448258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076448258&partnerID=8YFLogxK

U2 - 10.2217/imt-2019-0115

DO - 10.2217/imt-2019-0115

M3 - Review article

C2 - 31663411

AN - SCOPUS:85076448258

VL - 11

SP - 1507

EP - 1521

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 17

ER -